Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Evaluation of Dosing Interval of Higher Doses of Ranibizumab (BGB/IST)

This study has been completed.
Genentech, Inc.
Information provided by (Responsible Party):
Brandon G. Busbee, MD, Tennessee Retina Identifier:
First received: September 19, 2007
Last updated: November 21, 2013
Last verified: November 2013
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: November 2013
  Primary Completion Date: November 2013 (Final data collection date for primary outcome measure)